Contemporary management of treatment-related dermatologic toxicities in gynecologic cancers: a systematic review based on evidence from 2021 to 2025
Wang S., Hou R., Wang R., Liu C., Xu S.
Systematic Review, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Systematic Review
- Journal
- Front Med (Lausanne) (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41797784
- PMCID
- PMC12965135
- DOI
- 10.3389/fmed.2026.1751349
Abstract (original English)
Introduction Gynecologic cancers are commonly managed with chemotherapy, radiotherapy, and targeted therapies, which are effective but frequently associated with significant skin side effects. These dermatologic toxicities substantially reduce patients' quality of life and treatment adherence, highlighting the need for a comprehensive synthesis of the latest evidence to address this clinical challenge. Methods This systematic review summarizes the most up-to-date evidence (as of 2025) regarding treatment-induced skin damage in patients with gynecologic cancers. It focuses on synthesizing data related to the clinical manifestations, subclinical changes, risk factors, and management strategies of these skin toxicities. Results Key findings include three critical areas of focus: subclinical skin damage (early, mostly asymptomatic changes induced by medications such as paclitaxel), radiotherapy-related skin issues, and severe skin effects associated with novel targeted therapies. Additionally, innovative technologies (e.g., 3D printed radiotherapy devices) were identified as potential tools for preventing and mitigating dermatologic toxicities. Discussion The review emphasizes the importance of individualized intervention plans and multidisciplinary care models to effectively manage treatment-related skin toxicities. By synthesizing the latest evidence on manifestations, mechanisms
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.